Current challenges in personalizing warfarin therapy.


In an exciting era where novel oral anticoagulants, such as the factor Xa and direct thrombin inhibitors, are beginning to emerge as therapeutic options, the vitamin K antagonists (VKAs) such as warfarin, which have been in clinical use for over half a century, will remain an important part of the therapeutic landscape for the foreseeable future. The… (More)
DOI: 10.1586/ecp.11.15


4 Figures and Tables

Cite this paper

@article{McMillin2011CurrentCI, title={Current challenges in personalizing warfarin therapy.}, author={Gwendolyn A. McMillin and Sara R. Vazquez and Robert C. Pendleton}, journal={Expert review of clinical pharmacology}, year={2011}, volume={4 3}, pages={349-62} }